GENCARO BUCINDOLOL HCL
Live / Applied — Second extension granted (statement of use) (as of 06 Oct 2025)
What this means for you
Not registered yet, but its 22 Dec 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98327939
- Mark type
- Design + words
- Filed
- 22 Dec 2023
- Published for opposition
- 27 Aug 2024
- Attorney of record
- Andrea K. Shannon
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for use in the treatment of diseases and disorders in the cardiovascular, vascular and hematology fields, made in significant part of bucindolol hcl
Owner
- GENVARA BIOPHARMA, INC., WESTMINSTER, CO, US
- ARCA Biopharma, Inc., Westminster, CO, US
- ARCA Biopharma, Inc., Westminster, CO, US
Prosecution history
- 07 Oct 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 06 Oct 2025 — SOU EXTENSION 2 GRANTED
- 06 Oct 2025 — SOU EXTENSION 2 FILED
- 06 Oct 2025 — SOU TEAS EXTENSION RECEIVED
- 22 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Apr 2025 — SOU EXTENSION 1 GRANTED
- 21 Apr 2025 — SOU EXTENSION 1 FILED
- 21 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 25 Dec 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 22 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 27 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 27 Aug 2024 — PUBLISHED FOR OPPOSITION
- 07 Aug 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 24 Jul 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 23 Jul 2024 — ASSIGNED TO EXAMINER